Replies to post #10 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

$10 Billion per year for just CTL-019 may be high, but the Chimeric Antigen Receptor technology can be expanded to solid tumors given the right target. 5T4 could be an excellent target for various solid tumors.

Oxford BioMedica is working on CAR technology with 5T4.

Combined LentiVector® and 5T4 platforms

The Company announces that it has initiated a pre-clinical research programme to establish proof-of-concept for a Chimeric Antigen Receptor (CAR) T-cell therapy for cancer that combines the specificity of the 5T4 antigen with the delivery efficiency of our proprietary Lentivector® platform. The goal is to exploit the power of CAR T-cells to target 5T4 expressed on tumour cells from a range of different cancers.

http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-interim-management-statement-3/

Good luck and GOD bless,

George